Delivery Order SPE2DB22D2214-SPE2DB25FS6MW
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,072.23 for Briviact 100 mg tablets (60-count) with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and reflects AmerisourceBergen's role as a critical pharmaceutical supplier within the federal medical procurement system. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order valued at $5,677.12 to AmerisourceBergen Drug Corp for the supply of Briviact 100 mg tablets (60-count units) on August 18, 2025, with an ultimate completion date of August 19, 2025. This competitive, non-set-aside award employs firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026....
- AmerisourceBergen Drug Corp was awarded a delivery order on September 4, 2025, by the Defense Logistics Agency (DLA) for 60 tablets of Briviact 100 mg, with a contract value of $1,041.97 and an ultimate completion date of September 5, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a tactical pharmaceutical supply fulfillment under DLA's...
- The Defense Logistics Agency awarded a delivery order valued at $5,569.98 to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Briviact 50 mg tablets (60-count units). This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement and is scheduled for completion by July 28, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $1,624.15 to AmerisourceBergen Drug Corp for Briviact 75 mg tablets (60-count units) on July 22, 2025, with completion scheduled for July 23, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor for federal medical...
- The Defense Logistics Agency awarded a delivery order valued at $5,136.01 to AmerisourceBergen Drug Corp for the supply of Briviact 50 mg tablets (60-count packaging) with a completion date of July 30, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under open competition. The pharmaceutical products will be delivered to the contractor's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on August 13, 2025, for the supply of Briviact 100 mg tablets in quantities of 60 units, valued at $2,268.17. This non-set-aside, firm fixed price delivery order is scheduled for completion by August 14, 2025, with performance based at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of the company's critical role as a pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $3,263.43 to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Briviact 100 mg tablets (60-count units). This firm fixed-price delivery order, with an ultimate completion date of August 26, 2025, represents a competitively awarded contract with no set-aside designation. The contract will be performed at AmerisourceBergen Drug Corp's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $7,100.94 on August 4, 2025, for the supply of Briviact 75 mg tablets (60-count packages) under a firm fixed-price contract with no set-aside designation. The award is supported by the Defense Logistics Agency's Medical Supply Chain, a division of the Department of Defense, with an ultimate completion date of August 5, 2025. This delivery order...
- The Defense Logistics Agency awarded a $5,802.87 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Briviact 100 mg tablets (60-count packages). This firm fixed-price, non-set-aside contract is classified as a child award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The pharmaceutical products will be delivered to the company's corporate office...
- SPE2DB22D2214Indefinite Delivery Contract
- SPE2DB22D2214-SPE2DB25FS6MWDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,135.62 to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Briviact 50 mg tablets (60-count packaging). This is a firm fixed price delivery order with no set-aside designation, executed under competitive procedures. The contract specifies a place of performance in Conshohocken, Pennsylvania, which serves as AmerisourceBergen's corporate headquarters. The order carries an ultimate completion date of September 11, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen maintains an extensive portfolio of federal contract awards covering a wide spectrum of medications and medical supplies across multiple therapeutic domains. The DLA's Pharmaceutical Prime Vendor Global Program represents a strategic approach to medical supply chain management, with plans for multiple regional awards to support the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 9/10/25 |